Can acyclovir resistance lead to increased risk of complications?

Can resistance to acyclovir make complications more likely?

Acyclovir resistance in herpes simplex virus (HSV) occurs when the virus develops mutations that let it survive exposure to the drug. These changes often affect the viral thymidine kinase or DNA polymerase enzymes that acyclovir needs to become active. When resistance develops, antiviral treatment fails to suppress the virus effectively.

What happens if resistance develops during treatment?

Treatment failure shows up as persistent lesions, ongoing pain, or virus isolation despite adequate dosing. In immunocompromised patients, such failure can allow unchecked viral replication. This can eroding mucosal surfaces and permit secondary bacterial infections. In transplant recipients and HIV patients, prolonged untreated infection increases the risk of visceral dissemination to lungs, liver, or brain.

How does resistance affect long-term outcomes?

Long-time HSV carriers with resistant strains report higher rates of frequent recurrences and prolonged healing times. In severe cases, virus reaches the central nervous system, raising concern for encephalitis or retinitis. Clinical data show that acyclovir-resistant HSV isolates are more common in bone-marrow transplant patients and AIDS patients with low CD4 counts, rather than in healthy individuals.

Why do companies test for resistance before prescribing alternatives?

Resistance testing identifies whether the virus still responds to acyclovir. Tests measure plaque reduction or genotypic sequencing for known mutations. Tests result in a switch to foscarnet or cidofovir once resistance is confirmed. These second-line agents carry toxicity risks such as nephrotoxicity and electrolyte imbalance. Toxicity concerns drive careful monitoring during their use.

Can other drugs step in before complications arise?

Foscarnet and cidofovir remain active against most acyclovir-resistant HSV strains. Brincidofovir is under investigation for broader spectrum and lower toxicity. Brincidofovir testing shows activity in vitro and in laboratory animals, but clinical experience is still limited.